INHIBITION OF VIRAL AND CELLULAR PROMOTERS BY HUMAN WILD-TYPE P53

被引:224
|
作者
SUBLER, MA [1 ]
MARTIN, DW [1 ]
DEB, S [1 ]
机构
[1] UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,SAN ANTONIO,TX 78284
关键词
D O I
10.1128/JVI.66.8.4757-4762.1992
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mutation of the p53 tumor suppressor gene is a recurring event in a variety of human cancers. Wild-type p53 may regulate cell proliferation and has recently been shown to repress transcription from several cellular promoters. We studied the effects of wild-type and mutant human p53 on the human proliferating-cell nuclear antigen promoter and on several viral promoters including the simian virus 40 early promoter-enhancer, the herpes simplex virus type 1 thymidine kinase and UL9 promoters, the human cytomegalovirus major immediate-early promoter-enhancer, and the long terminal repeat promoters of Rous sarcoma virus, human immunodeficiency virus type 1, and human T-cell lymphotropic virus type I. HeLa cells were cotransfected with a wild-type or mutant p53 expression vector and plasmids containing a chloramphenicol acetyltransferase reporter gene under viral (or cellular) promoter control. Expression of wild-type p53 correlated with a consistent and significant (6- to 76-fold) reduction of reporter enzyme activity. A mutation at amino acid 143 of p53 releases this inhibition significantly with all the promoters studied. Expression of a p53 mutated at any one of the five amino acid positions 143, 175, 248, 273, and 281 also correlated with a much smaller (one- to sixfold) reduction of reporter enzyme activity from the herpes simplex virus type 1 thymidine kinase promoter. These mutant forms of p53 are found in various cancer cells. Thus, failure of tumor suppression correlates with loss of the promoter inhibitory effect of p53.
引用
收藏
页码:4757 / 4762
页数:6
相关论文
共 50 条
  • [21] TRANSCRIPTIONAL REPRESSION IN NORMAL HUMAN KERATINOCYTES BY WILD-TYPE AND MUTANT P53
    ALVAREZSALAS, LM
    VELAZQUEZ, A
    LOPEZBAYGHEN, E
    WOODWORTH, CD
    GARRIDO, E
    GARIGLIO, P
    DIPAOLO, JA
    CANCER LETTERS, 1995, 91 (01) : 85 - 92
  • [22] HUMAN GLIOMAS WITH WILD-TYPE P53 EXPRESS BCL-2
    ALDERSON, LM
    CASTLEBERG, RL
    HARSH, GR
    LOUIS, DN
    HENSON, JW
    CANCER RESEARCH, 1995, 55 (05) : 999 - 1001
  • [23] Transduction of a wild-type p53 gene into human malignant melanoma cells
    Hakim, AA
    CANCER GENE THERAPY, 2001, 8 : S8 - S8
  • [24] Wild-Type p53 Regulates Apoptosis of Human Breast Cancer Cells
    Zhang, Xuliang
    Yu, Guozheng
    Cai, Lei
    Jian, Ming
    Cai, Lixia
    Xu, Dong
    DISCOVERY MEDICINE, 2024, 36 (191) : 2445 - 2453
  • [25] Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells
    Schlamp, CL
    Poulsen, GL
    Nork, TM
    Nickells, RW
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (20) : 1530 - 1536
  • [26] Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion
    Knippschild, U
    Oren, M
    Deppert, W
    ONCOGENE, 1996, 12 (08) : 1755 - 1765
  • [27] Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia
    Folkerts, Hendrik
    Hilgendorf, Susan
    Wierenga, Albertus T. J.
    Jaques, Jennifer
    Mulder, Andre B.
    Coffer, Paul J.
    Schuringa, Jan Jacob
    Vellenga, Edo
    CELL DEATH & DISEASE, 2017, 8 : e2927 - e2927
  • [28] Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia
    Hendrik Folkerts
    Susan Hilgendorf
    Albertus T J Wierenga
    Jennifer Jaques
    André B Mulder
    Paul J Coffer
    Jan Jacob Schuringa
    Edo Vellenga
    Cell Death & Disease, 2017, 8 : e2927 - e2927
  • [29] Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53
    Sugikawa, E
    Yazaki, N
    Tsunoda, S
    Nakanishi, N
    Ohashi, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 261 (02) : 256 - 263
  • [30] Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53
    Lisa S St. John
    Edward R Sauter
    Meenhard Herlyn
    Samuel Litwin
    Karen Adler-Storthz
    Cancer Gene Therapy, 2000, 7 : 749 - 756